CapVest sells Curium Pharma to continuation fund at $7B valuation

TPG, ICG and CVC Capital lead new vehicle for the French nuclear medicine company.

Close up 3d render. Vaccine manufacturing, machine puts caps on bottles vials passing on conveyor belt. Clear blue liquid.

UK-based CapVest Partners has launched a continuation fund for its nuclear medicine portfolio company Curium Pharma at a $7 billion valuation, marking one of the largest deals in the sector.

TPG GP Solutions, ICG and CVC Capital Partners led the new fund. Goldman Sachs Alternatives, Lunate, Pantheon and Ardian also participated in the fund, while TPG Life Sciences Innovations made a minority investment in the French company.

Paris-based Curium supplies radioactive tracers used in nuclear medicine to enable early diagnosis and treatment of cancer, as well as heart, brain and bone diseases. It supplies its 6,000 global customers, serving 14 million patients annually, according to its website.

CapVest is raising about $3.8 billion for the continuation fund, according to a Bloomberg report.

Latest Research

Q326_AerospaceDefense_SocialCards_1700x2200-vertical-cover.png

Aerospace & Defense Report: Defense on the Rise

The Q3 2026 Aerospace & Defense Report provides in-depth analysis of industry trends and evolving PE investment strategies, including deals data and maps of key PE-backed companies and investors.

Growth investor 21 Invest also acquired Milan-based nuclear medicine product provider Else Solutions in September. Else reported a 47% and 60% growth in revenue and EBITDA to €20 million ($23 million) and €4 million, respectively, in 2024.

GP-led secondaries are increasingly used to generate liquidity and secure returns for GPs and LPs amid an IPO drought. According to PitchBook’s Q3 2025 European PE Breakdown, €52.9 billion has been transacted in GP-led secondary activities in North America and Europe as of September 30.